Monitor issues related to cancer diagnostic testing and medicare coverage of cancer screening tests.
Support increased funding and reforms for the USPSTF to initiate early action reviews.
Monitor issues related to advanced diagnostics and precision cancer care and track proposals to develop novel screening technologies.
Duration: August 20, 2019
to
present
General Issues: Medicare/Medicaid , Health Issues , Labor Issues/Antitrust/Workplace , Veterans
Spending: about $3,787,500 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2019: U.S. Senate, House of Representatives, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), White House Office, Agency for Healthcare Research & Quality (AHRQ), Veterans Affairs - Dept of (VA)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, GUARDANT HEALTH had in-house lobbyists. The report was filed on April 4.
Original Filing: 301546561.xml
Lobbying Issues
Monitor issues related to cancer diagnostic testing and medicare coverage of cancer screening tests.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS) White House Office
Lobbying Issues
Support increased funding and reforms for the USPSTF to initiate early action reviews.
Monitor issues related to advanced diagnostics and precision cancer care and track proposals to develop novel screening technologies.
Agencies Lobbied
U.S. Senate U.S. House of Representatives White House Office Agency for Healthcare Research & Quality (AHRQ) Health & Human Services - Dept of (HHS)
4th Quarter, 2023
In Q4, GUARDANT HEALTH had in-house lobbyists. The report was filed on Jan. 19.
Original Filing: 301530443.xml
Lobbying Issues
Monitor issues related to cancer diagnostic testing and medicare coverage of cancer screening tests.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS) White House Office
Lobbying Issues
Support increased funding and reforms for the USPSTF to initiate early action reviews.
Monitor issues related to advanced diagnostics and precision cancer care and track proposals to develop novel screening technologies.
Agencies Lobbied
U.S. Senate U.S. House of Representatives White House Office Agency for Healthcare Research & Quality (AHRQ) Health & Human Services - Dept of (HHS)
3rd Quarter, 2023
In Q3, GUARDANT HEALTH had in-house lobbyists. The report was filed on Oct. 19, 2023.
Original Filing: 301505921.xml
Lobbying Issues
Monitor issues related to cancer diagnostic testing and medicare coverage of cancer screening tests.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS) White House Office
Lobbying Issues
Support increased funding and reforms for the USPSTF to initiate early action reviews.
Agencies Lobbied
U.S. Senate U.S. House of Representatives White House Office
2nd Quarter, 2023
In Q2, GUARDANT HEALTH had in-house lobbyists. The report was filed on July 20, 2023.
Original Filing: 301486666.xml
Lobbying Issues
Monitor issues related to cancer diagnostic testing and medicare coverage of cancer screening tests.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
Lobbying Issues
Support increased funding and reforms for the USPSTF to initiate early action reviews.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2023
In Q1, GUARDANT HEALTH had in-house lobbyists. The report was filed on April 21, 2023.
Original Filing: 301468635.xml
Lobbying Issues
Monitor issues related to cancer diagnostic testing and medicare coverage of cancer screening tests.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
Lobbying Issues
Support increased funding and reforms for the USPSTF to initiate early action reviews.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2022
In Q4, GUARDANT HEALTH had in-house lobbyists. The report was filed on Jan. 19, 2023.
Original Filing: 301433947.xml
Lobbying Issues
Issues related to cancer diagnostic testing; Medicare coverage of cancer screening tests; H.R. 1946/S. 1873 Medicare Multi-Cancer Early Detection Screening Coverage
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
Lobbying Issues
Increased funding for US Preventive Services Task Force; VALID Act of 2021 (HR 4128/S.2209); cancer prevention; diversity in clinical trials
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to marketplace and health care access
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Labor Issues/Antitrust/Workplace
Lobbying Issues
Issues related to the VA's National Precision Oncology Program
Agencies Lobbied
U.S. Senate U.S. House of Representatives Veterans Affairs - Dept of (VA)
3rd Quarter, 2022
In Q3, GUARDANT HEALTH had in-house lobbyists. The report was filed on Oct. 20, 2022.
Original Filing: 301418096.xml
Lobbying Issues
Issues related to cancer diagnostic testing; Medicare coverage of cancer screening tests; H.R. 1946/S. 1873 Medicare Multi-Cancer Early Detection Screening Coverage
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
Lobbying Issues
Increased funding for US Preventive Services Task Force; VALID Act of 2021 (HR 4128/S.2209); cancer prevention; diversity in clinical trials
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to marketplace and health care access
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Labor Issues/Antitrust/Workplace
Lobbying Issues
Issues related to the VA's National Precision Oncology Program
Agencies Lobbied
U.S. Senate U.S. House of Representatives Veterans Affairs - Dept of (VA)
2nd Quarter, 2022
In Q2, GUARDANT HEALTH had in-house lobbyists. The report was filed on July 20, 2022.
Original Filing: 301390970.xml
Lobbying Issues
Issues related to cancer diagnostic testing; Medicare coverage of cancer screening tests; H.R. 1946/S. 1873 Medicare Multi-Cancer Early Detection Screening Coverage
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
Lobbying Issues
Increased funding for US Preventive Services Task Force; VALID Act of 2021 (HR 4128/S.2209); cancer prevention; diversity in clinical trials
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to marketplace and health care access
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Labor Issues/Antitrust/Workplace
1st Quarter, 2022
In Q1, GUARDANT HEALTH had in-house lobbyists. The report was filed on April 20, 2022.
Original Filing: 301365436.xml
Lobbying Issues
Issues related to cancer diagnostic testing; Medicare coverage of cancer screening tests; H.R. 1946/S. 1873 Medicare Multi-Cancer Early Detection Screening Coverage
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
Lobbying Issues
Increased funding for US Preventive Services Task Force; VALID Act of 2021 (HR 4128/S.2209); cancer prevention; diversity in clinical trials
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2021
In Q4, GUARDANT HEALTH had in-house lobbyists. The report was filed on Jan. 21, 2022.
Original Filing: 301339354.xml
Lobbying Issues
Issues related to cancer diagnostic testing; Medicare coverage of cancer screening tests; H.R. 1946/S. 1873 Medicare Multi-Cancer Early Detection Screening Coverage
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
Lobbying Issues
VALID Act of 2021 (HR 4128/S.2209); cancer prevention; diversity in clinical trials
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2021
In Q3, GUARDANT HEALTH had in-house lobbyists. The report was filed on Oct. 19, 2021.
Original Filing: 301303620.xml
Lobbying Issues
Issues related to cancer diagnostic testing; Medicare coverage of cancer screening tests; H.R. 1946/S. 1873 Medicare Multi-Cancer Early Detection Screening Coverage
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
Lobbying Issues
VALID Act of 2021 (HR 4128/S.2209); cancer prevention; diversity in clinical trials
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2021
In Q2, GUARDANT HEALTH had in-house lobbyists. The report was filed on July 20, 2021.
Original Filing: 301284205.xml
Lobbying Issues
Issues related to cancer diagnostic testing; Medicare coverage of cancer screening tests; H.R. 1946/S. 1873 Medicare Multi-Cancer Early Detection Screening Coverage
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
Lobbying Issues
IVD regulation; cancer prevention; diversity in clinical trials
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2021
In Q1, GUARDANT HEALTH had in-house lobbyists. The report was filed on April 21, 2021.
Original Filing: 301268535.xml
Lobbying Issues
Issues related to cancer diagnostic testing; Medicare coverage of cancer screening tests; H.R. 1946 Medicare Multi-Cancer Early Detection Screening Coverage
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
Lobbying Issues
IVD regulation; cancer prevention; issues related to COVID-19 pandemic response and clinical laboratories
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2020
In Q4, GUARDANT HEALTH had in-house lobbyists. The report was filed on Jan. 20, 2021.
Original Filing: 301240687.xml
Lobbying Issues
Issues related to cancer diagnostic testing; Medicare coverage of cancer screening tests; H.R. 8845/S.5051 Medicare Multi-Cancer Early Detection Screening Coverage Act of 2020
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
Lobbying Issues
Surprise medical billing and access to colon cancer screening provisions within H.R. 133, the Consolidated Appropriations Act 2021; H.R. 6102/S. 3404 - VALID Act; issues related to COVID-19 pandemic response and clinical laboratories
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2020
In Q3, GUARDANT HEALTH had in-house lobbyists. The report was filed on Oct. 20, 2020.
Original Filing: 301219535.xml
Lobbying Issues
Issues related to cancer diagnostic testing; Medicare coverage of cancer screening tests; H.R. 1765 Donald Payne Sr. Colorectal Cancer Detection Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
Lobbying Issues
Legislation to address surprise medical bills - S.1895 Lower Health Care Costs Act, H.R. 5826 Consumer Protections Against Surprise Medical Bills Act of 2020; H.R. 6102/S. 3404 - VALID Act; issues related to COVID-19 pandemic response and clinical laboratories; issues related to self-referral
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2020
In Q2, GUARDANT HEALTH had in-house lobbyists. The report was filed on July 20, 2020.
Original Filing: 301196804.xml
Lobbying Issues
Issues related to cancer diagnostic testing; Medicare coverage of cancer screening tests; H.R. 1765 Donald Payne Sr. Colorectal Cancer Detection Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
Lobbying Issues
Legislation to address surprise medical bills - S.1895 Lower Health Care Costs Act, H.R. 5826 Consumer Protections Against Surprise Medical Bills Act of 2020; issues related to COVID-19 pandemic response and clinical laboratories; issues related to self-referral
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2020
In Q1, GUARDANT HEALTH had in-house lobbyists. The report was filed on April 20, 2020.
Original Filing: 301175867.xml
Lobbying Issues
Issues related to cancer diagnostic testing; Medicare coverage of cancer screening tests; H.R. 1765 Donald Payne Sr. Colorectal Cancer Detection Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
Lobbying Issues
Legislation to address surprise medical bills - S.1895 Lower Health Care Costs Act; H.R. 1570/S. 668 - Removing Barriers to Colorectal Cancer Screening Act; H.R. 6102/S. 3404 - VALID Act; issues related to COVID-19 pandemic response and clinical laboratories - H.R. 748 CARES Act; issues related to self-referral
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2019
In Q4, GUARDANT HEALTH had in-house lobbyists. The report was filed on Jan. 20, 2020.
Original Filing: 301122586.xml
Lobbying Issues
Issues related to cancer diagnostic testing; issues related to the CY 2020 Hospital Outpatient Prospective Payment proposed rule and the Laboratory Date of Service Policy
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
Lobbying Issues
Legislation to address surprise medical bills - S.1895 Lower Health Care Costs Act
3rd Quarter, 2019
In Q3, GUARDANT HEALTH had in-house lobbyists. The report was filed on Oct. 20, 2019.
Original Filing: 301072522.xml
Lobbying Issues
Issues related to cancer diagnostic testing; issues related to the CY 2020 Hospital Outpatient Prospective Payment proposed rule and the Laboratory Date of Service Policy
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
Lobbying Issues
S.1895 Lower Health Care Costs Act
3rd Quarter, 2019
GUARDANT HEALTH filed a lobbying registration on Sept. 3, 2019 for in-house lobbying efforts, effective Aug. 20, 2019.
Original Filing: 301061592.xml
Issue(s) they said they’d lobby about: Issues related to liquid biopsy and precision medicine; issues related to the Medicare coverage and reimbursement for lab developed tests. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate